AU2011324871B2 - Anti-HER3 antibodies and compositions - Google Patents

Anti-HER3 antibodies and compositions Download PDF

Info

Publication number
AU2011324871B2
AU2011324871B2 AU2011324871A AU2011324871A AU2011324871B2 AU 2011324871 B2 AU2011324871 B2 AU 2011324871B2 AU 2011324871 A AU2011324871 A AU 2011324871A AU 2011324871 A AU2011324871 A AU 2011324871A AU 2011324871 B2 AU2011324871 B2 AU 2011324871B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
her3
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011324871A
Other languages
English (en)
Other versions
AU2011324871A1 (en
Inventor
Helle Jacobsen
Klaus Koefoed
Mikkel Wandahl Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of AU2011324871A1 publication Critical patent/AU2011324871A1/en
Application granted granted Critical
Publication of AU2011324871B2 publication Critical patent/AU2011324871B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011324871A 2010-11-01 2011-10-31 Anti-HER3 antibodies and compositions Ceased AU2011324871B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
US61/408,782 2010-11-01
DKPA201000988 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
US61/531,407 2011-09-06
PCT/IB2011/054835 WO2012059858A1 (en) 2010-11-01 2011-10-31 Anti-her3 antibodies and compositions

Publications (2)

Publication Number Publication Date
AU2011324871A1 AU2011324871A1 (en) 2013-05-09
AU2011324871B2 true AU2011324871B2 (en) 2016-05-19

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011324871A Ceased AU2011324871B2 (en) 2010-11-01 2011-10-31 Anti-HER3 antibodies and compositions
AU2011324870A Ceased AU2011324870B2 (en) 2010-11-01 2011-10-31 pan-HER antibody composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011324870A Ceased AU2011324870B2 (en) 2010-11-01 2011-10-31 pan-HER antibody composition

Country Status (13)

Country Link
US (1) US9217039B2 (enExample)
EP (3) EP3156421B1 (enExample)
JP (2) JP6033783B2 (enExample)
KR (2) KR101862832B1 (enExample)
AU (2) AU2011324871B2 (enExample)
CA (2) CA2816519C (enExample)
DK (1) DK2635604T3 (enExample)
ES (2) ES2616961T3 (enExample)
IL (2) IL225954B (enExample)
MX (2) MX347981B (enExample)
PL (1) PL2635604T3 (enExample)
TW (1) TW201231066A (enExample)
WO (2) WO2012059858A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706255B1 (ko) * 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
JP5680671B2 (ja) 2009-12-22 2015-03-04 ロシュ グリクアート アーゲー 抗ｈｅｒ３抗体及びその使用
JP6033783B2 (ja) 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EA201301025A1 (ru) * 2011-03-15 2014-01-30 Мерримак Фармасьютикалс, Инк. Преодоление устойчивости к ингибиторам пути erbb
WO2012156975A1 (en) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
DK2726600T3 (en) * 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
BR112014024017A8 (pt) * 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
BR112014027291A2 (pt) * 2012-05-02 2017-08-08 Symphogen As composições de anticorpos pan-her humanizados
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
DK3508502T5 (da) 2013-09-20 2024-09-02 Bristol Myers Squibb Co Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP3387017A1 (en) 2015-12-11 2018-10-17 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN114984209B (zh) 2017-04-05 2025-08-29 正大天晴药业集团股份有限公司 靶向pd-1、tim-3及lag-3的组合疗法
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
RS64787B1 (sr) 2017-05-30 2023-11-30 Bristol Myers Squibb Co Lečenje lag-3-pozitivnih tumora
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
WO2020051333A1 (en) * 2018-09-07 2020-03-12 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
MA54944A (fr) * 2019-02-14 2021-12-22 Merus Nv Combinaisons de fractions de liaison se liant à egfr, her2 et her3
WO2021015237A1 (ja) * 2019-07-24 2021-01-28 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126303A (en) * 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US20020004587A1 (en) * 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
ATE338816T1 (de) 2003-01-07 2006-09-15 Symphogen As Verfahren zur herstellung rekombinanterpolyklonaler proteine
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2006007853A2 (en) 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
EP2647388A1 (en) * 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
WO2008104183A2 (en) 2007-03-01 2008-09-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
PL2152872T3 (pl) 2007-05-25 2011-03-31 Symphogen As Sposób wytwarzania rekombinowanego białka poliklonalnego
SG186013A1 (en) 2007-11-22 2012-12-28 Symphogen As A method for characterization of a recombinant polyclonal protein
CN102007146A (zh) 2008-04-23 2011-04-06 西福根有限公司 用于制备多克隆蛋白质的方法
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
US20110224094A1 (en) 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
JP5624114B2 (ja) * 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
SI2417156T1 (sl) * 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
KR20110124369A (ko) * 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항­ｅｒｂｂ­3／항­ｃ­ｍｅｔ 항체
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
IN2012DN01518A (enExample) * 2009-08-21 2015-06-05 Merrimack Pharmaceuticals Inc
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
CN102884084B (zh) * 2010-03-04 2016-12-07 西福根有限公司 抗her2抗体及组合物
CN102884085B (zh) * 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
CU24094B1 (es) 2010-08-20 2015-04-29 Novartis Ag Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
JP6033783B2 (ja) 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物

Also Published As

Publication number Publication date
EP2635605A1 (en) 2013-09-11
JP2014503188A (ja) 2014-02-13
MX348637B (es) 2017-06-22
PL2635604T3 (pl) 2017-09-29
CA2816520C (en) 2017-11-21
IL225954B (en) 2018-05-31
IL225954A0 (en) 2013-07-31
WO2012059857A3 (en) 2012-07-19
JP2014503189A (ja) 2014-02-13
KR101862832B1 (ko) 2018-05-30
MX2013004899A (es) 2013-07-15
WO2012059857A2 (en) 2012-05-10
ES2616961T3 (es) 2017-06-14
CA2816520A1 (en) 2012-05-10
DK2635604T3 (en) 2017-02-27
EP3156421A1 (en) 2017-04-19
TW201231066A (en) 2012-08-01
EP2635604A2 (en) 2013-09-11
AU2011324870A1 (en) 2013-01-31
EP2635605A4 (en) 2014-10-22
KR101773120B1 (ko) 2017-08-30
US20130287684A1 (en) 2013-10-31
CA2816519C (en) 2019-01-15
US9217039B2 (en) 2015-12-22
ES2692379T3 (es) 2018-12-03
KR20140026336A (ko) 2014-03-05
MX2013004897A (es) 2013-07-15
EP2635605B1 (en) 2018-07-25
JP6186277B2 (ja) 2017-08-23
MX347981B (es) 2017-05-22
IL225953A0 (en) 2013-07-31
AU2011324870B2 (en) 2015-01-29
EP2635604B1 (en) 2016-11-30
JP6033783B2 (ja) 2016-11-30
AU2011324871A1 (en) 2013-05-09
KR20140026337A (ko) 2014-03-05
EP3156421B1 (en) 2018-06-06
CA2816519A1 (en) 2012-05-10
WO2012059858A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
AU2011324871B2 (en) Anti-HER3 antibodies and compositions
US10221246B2 (en) Pan-HER antibody composition
US8609095B2 (en) Anti-HER2 antibodies and compositions
CN102884084B (zh) 抗her2抗体及组合物
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição
BR112013010718A2 (pt) composição de anticorpo pan-her, composição farmacêutica, método para produção e uso da referida composição

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired